Opendata, web and dolomites

MAMSCAN

New Method for Early Stage Breast Cancer Detection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAMSCAN project word cloud

Explore the words cloud of the MAMSCAN project. It provides you a very rough idea of what is the project "MAMSCAN" about.

clients    strategy    uk    commercialization    competitors    scanning    specialist    oy    solutions    invasive    finalise    device    patented    markets    fall    proprietary    neutral    private    anatomic    population    considerable    worked    ing    annually    certification    health    services    age    finland    treatment    affordable    societal    consists    care    solution    clinics    spain    alternative    speed    ipr    business    cancer    foreseen    ultrasound    amiqo    market    attain    found    direct    extensive    million    50    suspect    clinical    mortality    france    share    imaqen    customers    accuracy    acquisition    2016    gynecological    healthcare    smei    company    initial    half    82    images    economic    outside    mammography    planning    effect    lower    imaging    frequency    expensive    pointing    pressure    involve    diagnosis    detection    pipeline    decreased    launch    deadliest    sales    significantly    acquire    sweden    diagnostic    fueled    examination    screenings    first    doctor    wavelength    groups    price    finnish    ai    breast    30    2020    map    day    stage    preventive    enhanced    2026    women    76    radiating    acceptance    mu   

Project "MAMSCAN" data sheet

The following table provides information about the project.

Coordinator
IMAQEN OY 

Organization address
address: LIIKEHUONEISTO C JA D POHJOISRANTA 6 A
city: HELSINKI
postcode: 170
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Project website http://www.imaqen.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IMAQEN OY FI (HELSINKI) coordinator 50˙000.00

Map

 Project objective

Imaqen Oy is a Finnish healthcare technology company developing an imaging solution for the early detection of breast cancer. Since 2016, we have worked on our proprietary technology, Amiqo that has the same diagnostic accuracy as the key competitors, mammography and breast ultrasound, while it is non-invasive and non-radiating. Amiqo consists of an imaging device using a patented μm-wavelength scanning, a proprietary frequency analysis enhanced by AI and an anatomic map pointing out the suspect areas for diagnosis carried out by a specialist doctor. Our initial target customers are private health care clinics who already have gynecological services. They are under pressure of finding affordable solutions for preventive healthcare fueled by women’s increasing awareness of the importance of early detection. The economic effect is considerable: the operating costs are significantly lower, it enables more images taken/day and its acquisition cost is neutral or lower. The end-clients are women under 50 or over 70 who fall outside the population level mammography screenings. 50% of breast cancer cases are found in these age groups annually. For women, Amiqo examination will be less than half the price of any current alternative. Through lower mortality and decreased treatment costs, Amiqo has a direct impact at societal level as breast cancer is the most common, the deadliest and the most expensive cancer for women in Europe. The next steps involve extensive clinical testing to finalise the product design, acquire certification and attain clinical acceptance. The SMEI funding will speed up the business planning in our priority markets, Finland, Sweden, France, the UK and Spain, including IPR pipeline, clinical acceptance strategy, user and technical requirements. The commercialization stage will be achieved by €1,76 million with the launch foreseen in 2020. The first goal is a 30% market share of the non-invasive imaging market by 2026 resulting in sales of €82 million.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAMSCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAMSCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ELDICO ED (2019)

ELDICO ED, Shaping the Future of Crystallography - The First Pure Electron Diffraction Equipment for Nano-Crystallography

Read More  

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More